DelveInsight’s, “Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021,” report provides comprehensive insights about 4+ companies and 4+ pipeline drugs in Moderate and Severe Chronic Kidney Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

    Geography Covered
    • Global coverage

    Moderate and Severe Chronic Kidney Disease Understanding
    Moderate and Severe Chronic Kidney Disease: Overview
    Chronic kidney disease, also called chronic kidney failure, describes the gradual loss of kidney function. Kidney function is measured by how well the kidneys clean the blood. The glomerular filtration rate (GFR) is a good way to find out the patient’s stage of kidney disease. The stages range from very mild (stage 1) to kidney failure (stage 5). Stage 3A Moderate CKD (GFR = 45-59 mL/min), Stage 3B Moderate CKD (GFR = 30-44 mL/min), and Stage 4 Severe CKD (GFR = 15-29 mL/min). Determining the cause of CKD distinguishes whether the patient has a systemic condition or a localized condition in the kidney such as glomerular disease because this functionality affects management.

    "Moderate and Severe Chronic Kidney Disease - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate and Severe Chronic Kidney Disease pipeline landscape is provided which includes the disease overview and Moderate and Severe Chronic Kidney Disease treatment guidelines. The assessment part of the report embraces, in depth Moderate and Severe Chronic Kidney Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate and Severe Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.


    Report Highlights
    • The companies and academics are working to assess challenges and seek opportunities that could influence Moderate and Severe Chronic Kidney Disease R&D. The therapies under development are focused on novel approaches to treat/improve Moderate and Severe Chronic Kidney Disease.

    Moderate and Severe Chronic Kidney Disease Emerging Drugs Chapters
    This segment of the Moderate and Severe Chronic Kidney Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

    Moderate and Severe Chronic Kidney Disease Emerging Drugs
    • KBP-5074: KBP Biosciences
    KBP-5074 is a third-generation non-steroidal mineralocorticoid receptor antagonist (MRA) with a unique pharmacokinetic (PK) profile characterized by a longer half-life and increased mineralocorticoid receptor (MR) affinity than current MRAs. KBP-5074 is currently evaluating patients in a global Phase 2b study evaluating its ability to treat uncontrolled hypertension and cardiorenal disease in stage 3b/4 Chronic Kidney Disease (CKD) patients who are at high risk of hyperkalemia and for whom existing MRAs are contraindicated.
    • ELIXCYTE: UnicoCell Biomed
    ELIXCYTE is an allogeneic adipose stem cell product and is currently undergoing two human clinical trials. For chronic kidney disease (CKD) treatment (NCT02933827), the phase-II clinical trial is ongoing.
    Further product details are provided in the report??..

    Moderate and Severe Chronic Kidney Disease: Therapeutic Assessment
    This segment of the report provides insights about the different Moderate and Severe Chronic Kidney Disease drugs segregated based on following parameters that define the scope of the report, such as:
    • Major Players in Moderate and Severe Chronic Kidney Disease
    There are approx. 4+ key companies which are developing the therapies for Moderate and Severe Chronic Kidney Disease. The companies which have their Moderate and Severe Chronic Kidney Disease drug candidates in the most advanced stage, i.e. phase II include, KBP Bioscience.

    Phases
    DelveInsight’s report covers around 4+ products under different phases of clinical development like
    • Late stage products (Phase III)
    • Mid-stage products (Phase II)
    • Early-stage product (Phase I) along with the details of
    • Pre-clinical and Discovery stage candidates
    • Discontinued & Inactive candidates

    Route of Administration
    Moderate and Severe Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
    • Oral
    • Parenteral
    • intravitreal
    • Subretinal
    • Topical.
    • Molecule Type

    Products have been categorized under various Molecule types such as
    • Monoclonal Antibody
    • Peptides
    • Polymer
    • Small molecule
    • Gene therapy
    • Product Type
    Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

    Moderate and Severe Chronic Kidney Disease: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate and Severe Chronic Kidney Disease therapeutic drugs key players involved in developing key drugs.
    Pipeline Development Activities
    The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate and Severe Chronic Kidney Disease drugs.

    Moderate and Severe Chronic Kidney Disease Report Insights
    • Moderate and Severe Chronic Kidney Disease Pipeline Analysis
    • Therapeutic Assessment
    • Unmet Needs
    • Impact of Drugs

    Moderate and Severe Chronic Kidney Disease Report Assessment
    • Pipeline Product Profiles
    • Therapeutic Assessment
    • Pipeline Assessment
    • Inactive drugs assessment
    • Unmet Needs

    Key Questions
    Current Treatment Scenario and Emerging Therapies:
    • How many companies are developing Moderate and Severe Chronic Kidney Disease drugs?
    • How many Moderate and Severe Chronic Kidney Disease drugs are developed by each company?
    • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate and Severe Chronic Kidney Disease?
    • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate and Severe Chronic Kidney Disease therapeutics?
    • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
    • What are the clinical studies going on for Moderate and Severe Chronic Kidney Disease and their status?
    • What are the key designations that have been granted to the emerging drugs?

    Key Players
    • KBP Bioscience
    • UnicoCell Biomed

    Key Products
    • KBP-5074
    • ELIXCYTE